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Abstract
Background: The study objective was to assess the influence of neutropenia on outcome of critically ill cancer
patients by meta-analysis of individual data. Secondary objectives were to assess the influence of neutropenia on
outcome of critically ill patients in prespecified subgroups (according to underlying tumor, period of admission,
need for mechanical ventilation and use of granulocyte colony stimulating factor (G-CSF)).
Methods: Data sources were PubMed and the Cochrane database. Study selection included articles focusing on
critically ill cancer patients published in English and studies in humans from May 2005 to May 2015. For study
selection, the study eligibility was assessed by two investigators. Individual data from selected studies were
obtained from corresponding authors.
Results: Overall, 114 studies were identified and authors of 30 studies (26.3% of selected studies) agreed to
participate in this study. Of the 7515 included patients, three were excluded due to a missing major variable
(neutropenia or mortality) leading to analysis of 7512 patients, including 1702 neutropenic patients (22.6%). After
adjustment for confounders, and taking study effect into account, neutropenia was independently associated with
mortality (OR 1.41; 95% CI 1.23–1.62; P = 0.03). When analyzed separately, neither admission period, underlying
malignancy nor need for mechanical ventilation modified the prognostic influence of neutropenia on outcome.
However, among patients for whom data on G-CSF administration were available (n = 1949; 25.9%), neutropenia
was no longer associated with outcome in patients receiving G-CSF (OR 1.03; 95% CI 0.70–1.51; P = 0.90).
Conclusion: Among 7512 critically ill cancer patients included in this systematic review, neutropenia was
independently associated with poor outcome despite a meaningful survival. Neutropenia was no longer
significantly associated with outcome in patients treated by G-CSF, which may suggest a beneficial effect of G-CSF
in neutropenic critically ill cancer patients.
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Background
Cancer is a leading cause of death in North America and
Europe [1, 2], and cancer patients are at high risk for
life-threatening complications as a result of infection [3],
toxicity of intensive treatments [4] or targeted therapies
[5], warranting admission to the intensive care unit (ICU).
Despite evidence that ICU mortality rates have declined
significantly over the last two decades [6, 7], and although
the number and extent of comorbidities, pre-existing per-
formance status along with organ failure have been dem-
onstrated to be the main prognostic factors in this setting
[8–10], intensivists may be reluctant to admit specific can-
cer patient populations such as neutropenic patients.
Although meaningful survival has been described in neu-
tropenic patients [11, 12], the prognostic impact of neutro-
penia remains controversial. Neutropenia remains a
common side effect of cancer chemotherapy and, although
transient, may lead to immune dysfunction. Clinical conse-
quences of neutropenia are well known and include occur-
rence of sepsis or acute respiratory failure [13], worsening
of respiratory status during neutropenia recovery [14] and
need for specific management [15]. In contrast to critically
ill cancer patients, neutropenia was found to be an inde-
pendent risk factor of poor outcome in the general ICU
population [16]. The lack of prognostic impact in critically
ill cancer patients may thus reflect an absence of statistical
power or the influence of coexistent mechanisms of im-
mune deficiency in these patients. In a previous systematic
review performed on aggregated data, neutropenia was as-
sociated with an increase in relative risk of death of 10% in
critically ill cancer patients [17]. With regards to the limited
number of studies reporting an adjusted impact of neutro-
penia, however, this preliminary study failed to demonstrate
an independent impact of neutropenia on outcome [17].
The aim of this study was to assess influence of neutro-
penia on outcome of critically ill cancer patients by a
meta-analysis of individual data. Secondary objectives were
to assess influence of neutropenia on outcome of critically ill
patients in prespecified subgroups (according to underlying
tumor, period of admission, need for mechanical ventilation
and use of granulocyte colony stimulating factor (G-CSF)).
Methods
This systematic review and meta-analysis of individual data
was performed according to the guidelines on
Meta-analysis of Observational Studies in Epidemiology
[18]. This study was registered on the PROSPERO database
(CRD42015026347). This study was a preplanned follow-up
study of an initial meta-analysis on aggregated data [17].
Study outcome and definitions
The aim of this meta-analysis of individual data was to
determine the prognostic impact of neutropenia on out-
come of critically ill cancer patients.
Neutropenia was defined as a neutrophil count (or if
missing as a white blood cell count) lower than 1 G/L
(stage 3 or more according to Common Terminology Cri-
teria for Adverse Events version 4.03) (https://evs.nci.nih.-
gov/ftp1/CTCAE/CTCAE_4.03/CTCAE_4.03_2010-06-14_
QuickReference_5x7.pdf).
Outcome was defined as hospital mortality or day-28
mortality if the former was unavailable (Table 1). Choice
of this outcome variable was driven by availability of
data precluding use of longer follow-up such as day 90.
Although ICU mortality was available for most of the re-
ported studies, this variable is more prone to be influ-
enced by the discharge policy in participating centers
and a longer follow-up period was preferred [19].
Search strategy and eligibility assessment
First, public-domain databases including PubMed and
the Cochrane database were searched using Exploded
Medical Subject Headings and the appropriate corre-
sponding keywords: “NEOPLASM” OR “MALIG-
NANCY” OR “CANCER” AND “INTENSIVE CARE
UNIT” OR “ICU”. The research was restricted to publi-
cations in English and studies concerning humans from
May 2005 to May 2015. Studies published before 2005
not included to limit heterogeneity across studied popu-
lations that may have arisen with regard to prognostic
change of both critically ill and critically ill cancer pa-
tients [20, 21]. Abstracts were carefully checked and
studies focusing on children or patients aged younger
than 18 years old, case reports and studies failing to
focus on critically ill patients were excluded.
All remaining references were then downloaded for
consolidation, elimination of duplicates and further
analysis. Four investigators (Marie Bouteloup, Sophie
Perinel, DM, MD) independently determined the eligi-
bility of all studies identified in the initial research.
Last, studies with explicit redundancies were only in-
cluded once (for this study, redundancies were assessed
by QG and MD).
Each of the included studies obtained approval of a
local or a national ethic committee in accordance with
local legislation. Patients or their next of kin consented
to participate or were informed of the included study
and did not oppose participation according to local le-
gislation. With regard to its retrospective design and
lack of change of the primary outcome variable, the need
for additional ethic committee approval was waived ac-
cording to French Law.
Patients were not involved in the included studies’ de-
sign. The primary outcome measure was defined accord-
ing to its clinical relevance for both patients and carers.
Health care providers were involved in patient recruit-
ment. Last, the patients and physicians involved in the
analyzed studies are thanked in Acknowledgements.
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Data and quality assessment
Investigators of selected publications were contacted
twice and invited to participate in this study. Authors
who agreed to participate were asked to send a file
containing individual data including: age, gender,
year of admission, underlying malignancy (solid
tumor vs hematological malignancy), history of allo-
geneic stem cell transplantation, severity score, need
for organ support (invasive mechanical ventilation,
vasopressor use, renal replacement therapy), neutro-
penia during ICU stay, neutropenia duration, use of
granulocyte colony stimulating factor (G-CSF),
follow-up and outcome.
To enable study comparison, we transformed illness
severity scores (Acute Physiology and Chronic Health
Evaluation (APACHE) II and APACHE III) into the
equivalent Simplified Acute Physiology Score (SAPS) II,
using a previously described methodology [22]. When
neither the APACHE II score nor the APACHE III score
was available, the available severity score was trans-
formed into the SAPS II according to the estimated odds
of dying during the ICU stay.
Risk of bias of included studies was assessed using the
“risk bias in cohort study” tool developed by the
Cochrane group (http://methods.cochrane.org/sites/
methods.cochrane.org.bias/files/public/uploads/















Canet et al., 2013 [34] Hospital 200 34 (24–50) Yes 1 0 30.0 7
Depuydt et al., 2010 [33] Hospital 137 25 (20–30) No 1 2.2 62.8 7
Bird et al., 2012 [27] Hospital 199 21 (17–25) Yes 1 0 54.3 5
Hill et al., 2012 [28] Hospital 147 62 (48–80) No 5 0 73.5 5
Müller et al., 2013 [35] Hospital 34 57 (31–97.75) No 1 100 44.1 5
Namendys-Silva et al., 2012 [30] Hospital 184 40 (31–51) Yes 1 30.4 58.2 6
Yeo et al., 2012 [48] Hospital 227 54 (37–71) No 1 0 89.9 7
Oeyen et al., 2013 [36] Hospital 483 34 (22–48) Yes 1 82.4 16.4 6
Ferra et al., 2007 [37] Hospital 100 60 (44.25–71) Yes 1 0 64.0 5
Soares et al., 2006 [20] Hospital 309 56 (45–68) Yes 1 24.6 64.1 7
Soares et al., 2007 (Chest) [38] Hospital 143 44 (32.5–57) Yes 2 100 58.7 6
Soares et al., 2007 (Intensive Care
Med) [44]
Hospital 121 47 (37–62) Yes 1 0 56.2 6
Soares et al., 2008 [32] Hospital 1090 44 (32–56.75) Yes 1 81.8 51.2 7
Soares et al., 2010 [25] Hospital 717 29 (19–42) Yes 28 93 30.4 7
Souza-Dantas et al., 2011 [45] Hospital 188 62 (48.75–73) No 1 31.9 75.5 7
Soares et al., 2014 (46) Hospital 449 44 (33–55) Yes 22 100 38.8 5
Song et al., 2011 [26] Hospital 62 41 (25–51) No 1 21 69.4 6
Yoo et al., 2013 [42] Hospital 214 44 (35–59) No 1 46.3 49.1 7
Lee et al., 2015 [43] Hospital 525 61.5 (51–70) Yes 1 40.2 56.0 7
Mokart et al., 2007 [21] 28 days 51 49 (35.5–70.25) Yes 1 21.6 43.1 5
Mokart et al., 2012 [47] Hospital 111 45 (33–55) Yes 1 21.6 40.5 6
Adda et al., 2008 [41] Hospital 99 49 (39.5–57) No 1 0 61.6 6
Burghi et al., 2011 [40] 28 days 59 NA No 1 0 72.9 7
Legriel et al., 2010 [23] Hospital 101 55 (42–67) No 1 29.7 44.6 5
Xhaard et al., 2013 [29] Hospital 62 NA No 1 0 41.9 5
Azoulay et al., 2008 [22] Hospital 148 NA Yes 1 12.8 55.4 6
Azoulay et al., 2013 [8] 28 days 1011 29 (23–39) Yes 17 0 38.2 7
McGrath et al., 2010 [24] Hospital 185 39 (26–47) No 1 37.8 31.4 5
Wohlfarth et al., 2014 [31] Hospital 56 50 (39–60.5) No 1 14.3 41.1 5
Toffart et al., 2011) [39] Hospital 103 44 (33–57) No 3 100 31.1 7
SAPS Simplified Acute Physiology Score
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Tool%20to%20Assess%20Risk%20of%20Bias%20in%20Co
hort%20Studies.pdf; accessed February 2, 2017).
Statistical analysis
All quantitative variables were described using medians
(quartiles) while qualitative variables were described with
their frequencies (percentage). The overall association be-
tween mortality and patient characteristics was determined
with a one-step meta-analysis approach. Univariate analyses
were performed using a logistic regression model with ran-
dom study effects to obtain odds ratios (ORs) with their
two-sided 95% confidence intervals (CIs) as measures of
relative risk. Variables identified as being associated with
mortality in univariate analyses, with P < 0.20, were in-
cluded in a multivariate logistic regression model with a
random study effect. Chi-square heterogeneity tests were
used to test for statistical heterogeneity among studies. The
I2 index (expressing the proportion of variability of the re-
sults related to heterogeneity) was reported.
Strata analyses were performed using the statistical
plan already described for the following strata: patients
with ICU admission after 2007 (median ICU admission
period in the studied population), patients with
hematological malignancy, patients requiring mechanical
ventilation and patients receiving G-CSF.
All effect sizes with P < 0.05 were considered significant.
All analyses were carried out with software R, version
3.2.5. The lme4 and Meta package were used to take into
account the random effects and to produce forest plots.
Results
Our initial search yielded 1528 citations, of which 38 were
excluded due to duplication and 706 were excluded as ir-
relevant for the scope of this review. All abstracts of the
remaining 784 records were carefully checked and 131
full-text articles focusing on critically ill cancer patients’
prognosis were scrutinized for further evaluation. Seventeen
studies were excluded, including 10 studies with redundan-
cies, five studies lacking neutropenic, non-neutropenic pa-
tients or major data required for the analysis, and two
studies including only palliative patients. Among the
remaining 114 studies, authors of 30 studies (26.3% of se-
lected studies) agreed to participate in this study, leading to
a dataset of 7515 patients, including 1702 neutropenic pa-
tients (22.6%) (Fig. 1) [8, 23–51].
Fig. 1 Flow chart of study selection
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Characteristics of included studies
The included studies were published from 2006 to 2015.
Sixteen were prospective cohort studies (53%) and six
(20%) were multicentric cohort studies (Table 1). The
variable of outcome was hospital mortality in 27 studies
and 28-day mortality in three studies. Overall, the num-
ber of patients included per study was 166 (IQR 99–266)
and ranged from 34 [38] to 1090 [35].
Characteristics of the patients
Of the 7515 included patients, three were excluded due
to missing major variables (neutropenia or mortality)
leading to analysis of 7512 patients. Of these patients,
4943 were included in monocenter studies (65.8%) and
5841 (77.8%) in prospective studies (Table 2).
Median age was 60 years (49–69) and median SAPS II
was 42 (28–57) (Table 2). Overall, 3366 patients (44.8%)
had a solid tumor and 439 patients were allogeneic stem
cell transplant recipients (5.8%). Respectively, 3710 pa-
tients (49.4%), 3084 patients (41.1%) and 1201 patients
(16%) required invasive mechanical ventilation, vaso-
pressors or renal replacement therapy.
Outcome
Unadjusted mortality in the studied population was 47.1%
(n = 3538), including mortality of 60.2% (n = 1025) and
43.2% (n = 2504) in neutropenic and non-neutropenic pa-
tients, respectively (P < 0.001).
After adjustment for confounders, and taking study ef-
fect into account, neutropenia was independently associ-
ated with mortality (OR 1.41; 95% CI 1.23–1.62;
P = 0.03) (Table 3, Fig. 2).
Influence of neutropenia in predefined subgroups
When analyzed separately, neither admission period,
underlying malignancy nor need for mechanical ventila-
tion modified the influence of neutropenia on outcome
(Additional file 1: Tables S1–S3).
In patients admitted after 2007 (median admission
period; n = 3563, including 880 neutropenic patients),
neutropenia was independently associated with an in-
creased mortality (OR 1.40; 95% CI 1.16–1.70; P < 0.001).
In patients with hematological malignancy (n = 4149,
including 1470 neutropenic patients), neutropenia was
independently associated with an increased mortality
(OR 1.30; 95% CI 1.11–1.51; P < 0.001).
Among the included patients, data on use of G-CSF
was available for 1949 patients (25.9%). Among the 788
patients receiving G-CSF, 587 were neutropenic. After
adjustment for confounders (Additional file 1: Table S4),
neutropenia was not independently associated with out-
come (OR 1.03; 95% CI 0.70–1.51; P = 0.90).
Table 2 Patient characteristics
Variable Missing data, n
(%)
Overall population (n =
7515)
Neutropenic patients (n =
1702)a




Age (years) 15 (0.2%) 60 (49–69) 55 (41–64) 61 (51–70) <
0.001
ICU admission year 0 2007 (2004–2010) 2008 (2005–2010) 2007 (2004–2010) <
0.001
Underlying malignancy




0 (0%) 4149 (55.2%) 1470 (86.4%) 2679 (46.1%) <
0.001
Allogeneic HSCT 0 (0%) 439 (5.8%) 186 (10.9%) 253 (4.4%) <
0.001
SAPS II 503 (6.7%) 41 (28–57) 51 (34–68) 39 (26–54) <
0.001
Organ support at ICU admission
Mechanical ventilation 1 (0%) 3804 (50.6%) 964 (56.6%) 2839 (48.9%) <
0.001




58 (0.8%) 1201 (16%) 386 (22.7%) 815 (14%) <
0.001
Mortality 2 (0%) 3538 (47.1%) 1021 (60%) 2517 (43.3%) <
0.001
HSCT hematopoietic stem cell transplantation, SAPS Simplified Acute Physiology Score, ICU intensive care unit
aData on neutropenia unavailable in three patients (0.03%)
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Discussion
This large dataset resulting from systematic review of in-
dividual data confirms neutropenia to be independently
associated with mortality in critically ill cancer patients.
According to our results, the prognostic impact of neu-
tropenia was unchanged when stratifying for malignancy,
period of ICU admission or use of mechanical ventila-
tion. However, in patients treated with G-CSF, neutro-
penia was no longer associated with mortality,
suggesting that the use of G-CSF may influence the
prognostic impact of neutropenia in this setting.
Neutropenia remains an accepted side effect of most
treatments administered to hematological patients [52].
Neutropenia is associated with complications that in-
clude severe sepsis [53], acute respiratory failure [54]
and specific conditions such as neutropenic enterocolitis
[55]. Although these side effects are likely to influence
the outcome of critically ill patients, results of studies in
this field remain controversial. Although neutropenia re-
mains associated with a poor outcome in general ICU
populations [16], several recent studies failed to demon-
strate an impact of neutropenia on the outcome of
Table 3 Factors independently associated with mortality after
adjustment for confounders (mix-linear model taking study
effect into account)
Variable Odds ratio 95% CI P value
Neutropenia 1.41 1.23–1.62 0.03
Age < 50 years Reference – –
Age 50–59 years 1.11 0.95–1.28 0.18
Age 60–69 years 1.32 1.13–1.53 < 0.001
Age 69+ years 1.66 1.43–1.94 < 0.001
Solid tumors (vs HM) 0.69 0.58–0.81 < 0.001
Allogeneic HSCT 1.91 1.50–2.43 < 0.001
Mechanical ventilation 3.01 2.66–3.41 < 0.001
Vasopressors 2.07 1.83–2.35 < 0.001
Renal replacement therapy 1.50 1.29–1.75 < 0.001
CI confidence interval, HM hematological malignancy, HSCT hematopoietic
stem cell transplantation
Fig. 2 Summary of adjusted prognostic impact of neutropenia on mortality in the included studies. CI confidence interval, OR odds ratio, ICM
Intensive Care Med, n.c., not counted (no event)
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critically ill cancer patients [8, 12]. The numerous mech-
anisms of immune deficiency in these patients, along
with the prognostic influence of disease severity or need
for organ support therapies, might explain these negative
findings. A previous systematic review, based on aggre-
gated data, suggested that neutropenia was associated
with a 10% increase in overall mortality but the result
may have been confounded by studies with negative
findings due to lack of statistical power [17]. In fact, the
influence of neutropenia was no longer significant after
adjusting for confounders but in a limited study popula-
tion [17]. Results of our study confirm that, even after
adjustment for confounders, neutropenia is associated
with a poor outcome. These data strongly suggest that
neutropenia, conversely to the recently published recom-
mendations [15], should be considered a prognostic fac-
tor. Additional studies are needed to confirm our results
and to identify room for improvements in the manage-
ment of this specific population.
In most of the predefined subgroups, namely accord-
ing to underlying malignancy, use of mechanical ventila-
tion or according to ICU admission period, the impact
of neutropenia on outcome was unchanged. However, it
must be noted that the impact of neutropenia was no
longer associated with outcome in patients treated with
G-CSF. Prophylactic use of G-CSF in patients with
hematological malignancy or solid tumors has proven ef-
ficacy in decreasing the risk or duration of neutropenia,
in limiting the risk of infectious disease and in specific
settings decreasing both overall mortality and
infection-related mortality [56, 57]. Conversely, use of
G-CSF in patients with already overt infections (curative
G-CSF) was found to have a limited benefit in neutro-
penic patients [58, 59]. Data regarding interest of
prophylactic or curative use of G-CSF are limited to
studies with high risk of bias and suggest a limited effi-
cacy in this setting [60–62]. In addition, G-CSF remains
associated with potential side effects, including risk of
worsening respiratory status during neutropenia recov-
ery [63]. Our study is the first to date to suggest indir-
ectly that G-CSF may limit the prognostic impact of
neutropenia in critically ill patients. Although this result
is insufficient to modify existing recommendations, add-
itional interventional studies in this setting may be
warranted.
This study has several important limitations. Firstly,
despite the biological plausibility, this study at best dem-
onstrated a statistical association between neutropenia
and mortality. Whether this statistical association may
be due to a causal relationship remains to be demon-
strated. Secondly, the observed dependent association
that might have been affected by allocation bias not
taken into account by our analysis. In line with this,
available data did not allow adjustment for center or
volume effect, assessment of the impact of organizational
processes [64], influence of duration of neutropenia or in-
fluence of several management strategies including impact
of antifungal prophylaxis. Last, only a quarter of identified
studies were ultimately included. However, it must be
noted that the large dataset, and the analysis adjusting for
study influence and modeling of unrecorded data by using
a mixed effect model, should have, at least partly, taken
these effects into account. In line with this, several arbi-
trary choices were made during analysis as regards the
study inclusion period or cutoff point to define the ICU
admission period. The lack of other reliable cutoff points,
however, is to be noted when taking into account these
limits. Last, the influence of G-CSF was assessed only in-
directly, in a subset of patients in whom the use of G-CSF
was recorded, without information regarding the rational
for its prescription. Thus, our negative results might re-
flect either a lack of statistical power or an inclusion bias.
Nevertheless, our results are a strong plea for further
interventional studies to assess the influence of G-CSF in
critically ill patients with neutropenia.
Conclusion
This systematic review, comprising 7515 patients, sug-
gests a meaningful survival in neutropenic critically ill
patients despite an independent association with poor
outcome. Neither underlying malignancy, a period of ad-
mission nor use of mechanical ventilation significantly
modified this result. Interestingly, neutropenia was no
longer significantly associated with outcome in patients
treated with G-CSF. Thus, our results may suggest a
beneficial effect of G-CSF in critically ill cancer patients
and serve as a plea for additional studies in this field.
Key messages
 This systematic review of individual data suggests a
meaningful survival in neutropenic critically ill
patients despite an independent association with
poor outcome.
 Neutropenia is no longer significantly associated
with outcome in patients treated with G-CSF,
suggesting a beneficial effect of this therapy in
critically ill cancer patients.
 The independent association of neutropenia with
poor outcome suggest additional research to be
required in way to limit excess of mortality in this
subgroup of critically-ill patients.
 Potential beneficial effect of G-CSF in critically-ill
neutropenic patients is a plea for additional studies
assessing benefits of therapeutic G-CSF in this
subgroup of patients.
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Additional file
Additional file 1: Table S1. Factors independently associated with
mortality after adjustment for confounders among patients with ICU
admission after 2007 (mix-linear model taking study effect into account).
Table S2. Factors independently associated with mortality after
adjustment for confounders among patients with hematological
malignancy (mix-linear model taking study effect into account). Table S3.
Factors independently associated with mortality after adjustment for
confounders among patients requiring mechanical ventilation (mix-linear
model taking study effect into account). Table S4. Factors independently
associated with mortality after adjustment for confounders among
patients receiving G-CSF (mix-linear model taking study effect into ac-
count) (DOC 58 kb)
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